Testing effectiveness (Phase 2)Not Yet RecruitingNCT06750991What this trial is testingCD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p)Who this might be right forDLBCL Ruijin Hospital 34
Not applicableStudy completedNCT04452292What this trial is testingNext Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine CarcinomaWho this might be right forLarge-Cell Neuroendocrine Carcinoma Charles Kunos 2
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05778149What this trial is testingSafety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-MutationWho this might be right forAumolertinibAnlotinibTP53+2 more Tianjin Medical University Cancer Institute and Hospital 47
Large-scale testing (Phase 3)Active Not RecruitingNCT03836261What this trial is testingStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLWho this might be right forChronic Lymphocytic Leukemia Acerta Pharma BV 984
Early research (Phase 1)Looking for participantsNCT06908434What this trial is testingA Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C MutationWho this might be right forSolid Tumors Harboring a TP53 Y220C Mutation Changchun GeneScience Pharmaceutical Co., Ltd. 82
Testing effectiveness (Phase 2)Looking for participantsNCT07499271What this trial is testingGenetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationWho this might be right forDiffuse Large B-Cell Lymphoma (DLBCL) The First Affiliated Hospital of Soochow University 35
Testing effectiveness (Phase 2)Study completedNCT02758665What this trial is testingTrial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLLWho this might be right forLeukemia, Lymphocytic, Chronic University of Ulm 41
Not applicableStudy completedNCT04976439What this trial is testingPatogenic Mutation in 5 GenesWho this might be right forColorectal CancerAPC Gene MutationTP53 Gene Mutation+3 more Dr Cipto Mangunkusumo General Hospital 22
Not applicableUnknownNCT04812938What this trial is testingExploiting Pathogenic Tp53 Mutation for Early Diagnosis of Ovarian Cancer by Mean of Papanicolau TestWho this might be right forOvarian Cancer Azienda Ospedaliera San Giovanni Battista 190
Early research (Phase 1)Looking for participantsNCT07372625What this trial is testingInvestigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.Who this might be right forTP53 Y220C MutationAdvanced Solid Tumors PMV Pharmaceuticals, Inc 14
Testing effectiveness (Phase 2)Looking for participantsNCT07060989What this trial is testingSafety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C MutationWho this might be right forAdvanced Solid Tumors Nutshell Therapeutics (Shanghai) Co., LTD. 220
Not applicableStudy completedNCT00001148What this trial is testingDetecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the TumorWho this might be right forAstrocytomaGlioblastomaGlioma National Institute of Neurological Disorders and Stroke (NINDS) 25
Not applicableLooking for participantsNCT07419893What this trial is testingGermline Genetic Testing of the TP53 GeneWho this might be right forTP53 Gene MutationMulti-Gene Transcriptional ProfilingTP53 Gene Germline Mutation Carrier European Institute of Oncology 1,940
Large-scale testing (Phase 3)Study completedNCT02950051What this trial is testingStandard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 MutationWho this might be right forChronic Lymphocytic Leukemia German CLL Study Group 926
Testing effectiveness (Phase 2)Study completedNCT03732352What this trial is testing18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent GlioblastomaWho this might be right forEGFR Gene AmplificationEGFR Gene MutationGlioblastoma+3 more Jonsson Comprehensive Cancer Center 12
Testing effectiveness (Phase 2)UnknownNCT00082979What this trial is testingDuct Endoscopy in Assessing Cellular Atypia in the Breast Duct Fluid of Women With a Genetic Risk for Breast CancerWho this might be right forBreast Cancer Royal Marsden NHS Foundation Trust 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05918276What this trial is testingClinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLLWho this might be right forCLL/SLL Nanfang Hospital, Southern Medical University 24
Early research (Phase 1)Study completedNCT06054464What this trial is testingInvestigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy ParticipantsWho this might be right forHealthy Volunteers PMV Pharmaceuticals, Inc 28
Early research (Phase 1)Active Not RecruitingNCT02432963What this trial is testingVaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior TherapyWho this might be right forAdult Solid NeoplasmBladder CarcinomaColon Carcinoma+14 more City of Hope Medical Center 11
Not applicableUnknownNCT03524677What this trial is testingMutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative DiagnosisWho this might be right forPancreatic Cancer University of Roma La Sapienza 50